Education
About Us
Working with TipRanks
Follow Us
Mannkind Corp. (MNKD)
NASDAQ:MNKD
MNKD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.06 - $7.63
Previous CloseN/A
Volume434.88K
Average Volume (3M)2.13M
Market Cap
$1.38B
Enterprise Value$1.83B
Total Cash (Recent Filing)$29.05M
Total Debt (Recent Filing)$317.90M
Price to Earnings (P/E)49.6
Beta0.75
Next Earnings
May 07, 2025EPS Estimate
0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.09
Shares Outstanding303,855,620
10 Day Avg. Volume2,418,907
30 Day Avg. Volume2,134,523
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.55
Price to Cash Flow (P/CF)17.50
P/FCF Ratio16.80
Enterprise Value/Market Cap1.33
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit8.08
Enterprise Value/Ebitda27.67
Forecast
1Y Price Target
$10.00Price Target Upside125.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
MannKind News
PremiumCompany Announcements
MannKind’s Earnings Call Highlights Robust Growth and Strategic Success
PremiumCompany Announcements
MannKind Corporation Reports Strong 2024 Financial Growth
---
Bulls Say, Bears Say
Bulls Say
Cash And Financial StabilityThe company is now durably cash flow positive and mostly de-levered, which is seen as positive for the fundamental outlook.
FDA ApprovalsTwo FDA approvals in diabetes and pulmonary arterial hypertension (PAH) have validated MannKind's technology platform in transforming therapeutics with proven efficacy into inhaled formulation to improve dosing convenience while maintaining or even improving treatment outcomes.
Revenue GrowthTyvaso DPI, a dry powder inhaler that delivers treprostinil for PAH and pulmonary hypertension associated with interstitial lung disease (PH-ILD), is on track to exceed $1B in FY24 annual net revenue, less than three years after FDA approval.
Bears Say
Clinical Development RisksRisks include clinical development challenges, commercial risks associated with royalties, and potential financial needs for raising capital.
Promotional EffortsThe modest revenues since the FDA approval in 2014 were mainly due to limited promotional efforts leading to low physician/patient awareness.
Revenue DependenceThe application of technology to additional indications, with an initial focus on Orphan lung diseases where currently available therapies are generating several hundred million to multi-billion dollar revenues despite well-known side effects from systemic exposure, should provide MannKind with substantial long-term growth potential.
---
Ownership Overview
2.81% Insiders
11.01% Mutual Funds
0.81% Other Institutional Investors
72.31% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MNKD FAQ
What was Mannkind Corp.’s price range in the past 12 months?
Mannkind Corp. lowest stock price was $4.06 and its highest was $7.63 in the past 12 months.
What is Mannkind Corp.’s market cap?
Mannkind Corp.’s market cap is $1.38B.
When is Mannkind Corp.’s upcoming earnings report date?
Mannkind Corp.’s upcoming earnings report date is May 07, 2025 which is in 15 days.
How were Mannkind Corp.’s earnings last quarter?
Mannkind Corp. released its earnings results on Feb 26, 2025. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.036 by -$0.006.
Is Mannkind Corp. overvalued?
According to Wall Street analysts Mannkind Corp.’s price is currently Undervalued.
Does Mannkind Corp. pay dividends?
Mannkind Corp. does not currently pay dividends.
What is Mannkind Corp.’s EPS estimate?
Mannkind Corp.’s EPS estimate is 0.04.
How many shares outstanding does Mannkind Corp. have?
Mannkind Corp. has 303,855,620 shares outstanding.
What happened to Mannkind Corp.’s price movement after its last earnings report?
Mannkind Corp. reported an EPS of $0.03 in its last earnings report, missing expectations of $0.036. Following the earnings report the stock price went down -4.388%.
Which hedge fund is a major shareholder of Mannkind Corp.?
Currently, no hedge funds are holding shares in MNKD
---
MannKind Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.00 (125.23% Upside)
$10.00 (125.23% Upside)
Blogger Sentiment
Bullish
MNKD Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 3.7%
Last 30 Days ▼ 3.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
10.73%
12-Months-Change
Fundamentals
Return on Equity
-35.00%
Trailing 12-Months
Asset Growth
-17.12%
Trailing 12-Months
Company Description
Mannkind Corp.
MannKind Corporation (MNKD) is a biopharmaceutical company that focuses on the discovery, development, and commercialization of therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. The company's flagship product, Afrezza, is a rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. MannKind operates primarily in the healthcare sector, with a core emphasis on innovative drug delivery systems, particularly via inhalation technology.
---
MNKD Company Deck
---
MNKD Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial performance and growth in key areas such as Tyvaso DPI and Afrezza revenues, alongside a significant reduction in debt. However, there are challenges in the pipeline development and preparation for the pediatric launch of Afrezza, as well as a slight decline in V-Go revenues. Overall, the positive financial results and strategic initiatives outweigh the challenges faced.Read More>---
MNKD Stock 12 Month Forecast
Average Price Target
$10.00
▲(125.23% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
BioCryst
―
Agios Pharma
―
Beam Therapeutics
―
Kymera Therapeutics
―
Best Analysts Covering MNKD
1 Year
1 Year Success Rate
3/5 ratings generated profit
1 Year Average Return
+28.34%
reiterated a buy rating 5 months ago
Copying Andreas Argyrides's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +28.34% per trade.
---